[
  {
    "ts": "2026-01-07T10:00:00+00:00",
    "headline": "Scenic Biotech Enters License and Research Agreement with Ono Pharmaceutical",
    "summary": "Amsterdam, the Netherlands, January 7, 2026 – Scenic Biotech, a pioneer in the field of modifier therapies for severe diseases, today announced a license and research agreement with Ono Pharmaceutical Co., Ltd. to utilize Scenic’s Cell-Seq platform for the discovery of novel therapeutic targets. “This collaboration with Ono Pharmaceutical represents another strong validation of our platform’s ability to uncover new disease biology and identify novel targets for rare and common indications,” said",
    "url": "https://finance.yahoo.com/news/scenic-biotech-enters-license-research-100000020.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "0bf17e97-0ae1-3e1b-bdbe-c60d2c3d99fb",
      "content": {
        "id": "0bf17e97-0ae1-3e1b-bdbe-c60d2c3d99fb",
        "contentType": "STORY",
        "title": "Scenic Biotech Enters License and Research Agreement with Ono Pharmaceutical",
        "description": "",
        "summary": "Amsterdam, the Netherlands, January 7, 2026 – Scenic Biotech, a pioneer in the field of modifier therapies for severe diseases, today announced a license and research agreement with Ono Pharmaceutical Co., Ltd. to utilize Scenic’s Cell-Seq platform for the discovery of novel therapeutic targets. “This collaboration with Ono Pharmaceutical represents another strong validation of our platform’s ability to uncover new disease biology and identify novel targets for rare and common indications,” said",
        "pubDate": "2026-01-07T10:00:00Z",
        "displayTime": "2026-01-07T10:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/f3c92d6a92a356b689039c33cf879964",
          "originalWidth": 1200,
          "originalHeight": 434,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lAjiTNmRG0.Ss9XknecrMQ--~B/aD00MzQ7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/f3c92d6a92a356b689039c33cf879964.cf.webp",
              "width": 1200,
              "height": 434,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/D_peJ4xkwgcevfSdGfXIeQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/f3c92d6a92a356b689039c33cf879964.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/scenic-biotech-enters-license-research-100000020.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/scenic-biotech-enters-license-research-100000020.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "OPHLF"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "ALNY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]